Zacks Investment Research upgraded shares of Q BioMed Inc (NASDAQ:QBIO) from a sell rating to a hold rating in a report released on Wednesday morning.

According to Zacks, “Q BioMed Inc. is a biomedical acceleration and development company. It focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. Q BioMed Inc. is based in New York. “

Shares of Q BioMed (NASDAQ:QBIO) opened at 3.90 on Wednesday. The firm’s 50-day moving average is $4.02 and its 200 day moving average is $4.26. The firm’s market capitalization is $41.11 million. Q BioMed has a 52 week low of $2.39 and a 52 week high of $12.61.

WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/26/q-biomed-inc-qbio-upgraded-at-zacks-investment-research.html.

Q BioMed Company Profile

Q BioMed, Inc, formerly ISMO Tech Solutions, Inc, is a biomedical acceleration and development company. The Company is focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. The Company intends to acquire multiple assets over time and across a spectrum of healthcare related products, companies and sectors.

Get a free copy of the Zacks research report on Q BioMed (QBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Q BioMed Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed Inc and related stocks with our FREE daily email newsletter.